Market report: ResMed announces record quarterly results
Friday, 28 January, 2011
ResMed (ASX:RMD), maker of sleep and respiratory medical devices, announced today record revenue and income for the last quarter of 2010, although investors in the ASX took 2.5% off the company's stock price in morning trading.
The company posted a revenue for the quarter ending December 31, 2010, of US$306 million, which is up 11% on the same quarter for 2009, largely on the back of sales of its S9 AutoSet sleep therapy system.
The lion's share of the growth occurred in the European and Asia-Pacific regions, which saw a 12% year-on-year growth, or 17% at a constant currency basis. Growth in the United States was lower, at 10%.
Expenses also increased over the quarter, primarily due to increased demand for sales support.
Research and development expenses were US$22 million, or 7% of revenue, an increase of 15% (or 10% at constant currency) year-on-year.
Even with the positive revenue news, investors on the ASX were drove down the price of ResMed shares by 2.5% in early trading, although they bounced back at midday to around $3.18, down 1.85% on Thursday's close.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
